To determine whether the observed HA-CPN- mediated regulation of CD44 receptor levels can affect TIC populations in glioblastoma patients, TICs derived from three individual GBM patient samples were treated with the nanoparticles and/or vehicle control. This evidence concerns the gene CPN1 and glioblastoma.